|
KMID : 1146320140020020124
|
|
Journal of Health Technology Assessment
2014 Volume.2 No. 2 p.124 ~ p.129
|
|
|
Cost-Effectiveness of Dabigatran Etexilate versus Warfarin for the Prevention of Stroke and Systemic Embolism in Korea Patients with Non-Valvular Atrial Fibrillation
|
|
Kim Joon-Su
Oh Yoon-Hwan
Kim Jung-Dae
|
|
|
Abstract
|
|
|
Objectives: The aim of this economic evaluation is to estimate the cost-effectiveness of dabigatran etexilate, an orally active thrombin inhibitor that has predictable and stable pharmacokinetics and a wide therapeutic margin, as treatment for the prevention of stroke in non-valvular AF patients who are warfarin eligible according to their stroke risk.
Methods: A Markov model estimated the costeffectiveness of dabigatran etexilate versus warfarin. A Markov model simulated AF patients at moderate to high risk of stroke while tracking clinical events [primary and recurrent ischaemic strokes, systemic embolism, transient ischaemic attack, haemorrhage (intracranial, extracranial, and minor), acute myocardial infarction and death] and resulting functional disability. Acute event costs and resulting long-term follow-up costs incurred by disabled stroke survivors were based on published literature and national statistics. Modelled outcomes over a lifetime horizon included clinical events, quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios.
Results: Dabigatran is cost effective vs. warfarin in prescribed setting, which results in an ICER of 18,711,096 KRW/QALY. When compared to warfarin, dabigatran costs 6,574,192 KRW more per patient while increases QALY by 0.21 year per patient.
Conclusion: This study demonstrates that dabigatran etexilate is a highly cost-effective alternative, using the ICER threshold (GDP per capita) as Health Insurance Review & Assessment Service(HIRA) recommended, to current care for the prevention of stroke and systemic embolism among Korean non-valvular AF patients.
|
|
|
KEYWORD
|
|
|
Dabigatran, Warfarin, Cost-effectiveness, Stroke, Systemic embolism, Atrial fibrillation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|